TEVA
Teva- Pharmaceutical Industries Ltd ADR
$34.64+3.59%
Setup
②PullbackPullback
Buy Zone
$33.64-$35.32
Sector
Drug Manufacturers - Specialty & Generic
Industry
Drug Manufacturers - Specialty & Generic
66
Recommendation
Watch
Watch②· 1d
Pullback fired, but quality 66 < 70 — not a leader
TEVA chart
Loading chart…
Overall Quality66
RS Rating
88
relative strength
Fundamentals
69
Solid fund-Q
Volume Demand
82
-22% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - Specialty & Generic
Trade Plan
Watch
Entry
$33.64
Entry Zone
$33.64-$35.32
Stop / Risk
$30.95
RS Rating
88
Volume confirmed
Yes
Targets
$40.37 / $42.05
Pullback · 21-EMA Bounce
5 ✓ 3 ✗
Entry $33.64–$35.32Stop $30.95Target $40.37 / $42.05
Market regimeRange
Quality66
RS Rating88
21-EMAReclaimed
Above 50-MA+1.89%
Above 200-MA+17.83%
In Buy ZoneNo
Not extendedOK
Invalidation · Close below 21-EMA
How this came together
66
MarketRange
Setup②PullbackPullback
ConfidenceMedium · 643 trades · 33% win · +0.20R
Fund-Q69 · Solid
StatusWatch②
Stock Data
52-Week Range15 – 37
Price % Chg YTD10.99%
Price % Chg 4wk4.72%
50-Day Avg Vol6.2 Mil
P/E Ratio24.7
Market Cap$39B
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Company Fundamentals
EPS % Chg (Qtr)69.9%
Sales % Chg (Qtr)3.6%
EPS Growth 5y—
Sales Growth 5y0.8%
Annual ROE21.73%
Gross Margin52.19%
Operating Margin23.22%
Net Margin8.98%
Debt / Equity2.05
Setup levels
Current price
$34.64
Pivot
$33.64
Distance to buy
-7.2%
52-week range
14.99-37.34
Trigger evidence
uptrend: 50>200 MA, rising
pullback reclaimed the 21-EMA 33.64
turned up off the line
Pattern levels: 21-EMA 33.64
Financial health checks
3/5
Return on equity above 15%
ROE 21.73%
Net margin above 10%
Net margin 8.98%
EPS growing quarter on quarter
EPS q/q 69.9%
Sales growing quarter on quarter
Sales q/q 3.6%
Debt to equity below 1.0
D/E 2.05
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE21.73%
vs sector -1.3%
Net margin8.98%
vs sector -10.3%
Gross margin52.19%
vs sector -19.5%
EPS growth q/q69.9%
vs sector +50.7%
Sales growth q/q3.6%
vs sector -17.6%
Debt / equity2.05
vs sector +1.33
Business quality
69
GradeSolid
EPS rating72
P/E24.7
Market cap$39B
IndustryDrug Manufacturers - Specialty & Generic
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-06-28
Trigger date
2026-07-02
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.